Publications

Detailed Information

The effects of psychopathology on subjective experience of side effects of antipsychotics in patients with schizophrenia

DC Field Value Language
dc.contributor.authorHwang, Samuel Suk-Hyun-
dc.contributor.authorJung, Dong Chung-
dc.contributor.authorKim, Se Hyun-
dc.contributor.authorAhn, Yong Min-
dc.contributor.authorKim, Yong Sik-
dc.date.accessioned2012-07-04T04:57:50Z-
dc.date.available2012-07-04T04:57:50Z-
dc.date.issued2010-03-
dc.identifier.citationINTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY; Vol.25 2; 83-90ko_KR
dc.identifier.issn0268-1315-
dc.identifier.urihttps://hdl.handle.net/10371/78401-
dc.description.abstractThis study was conducted to delineate the relationship between self-reported side effects and psychopathology in schizophrenia patients. Patients with schizophrenia completed the Liverpool University Neuroleptic Side Effects Rating Scale for subjective side effects and were evaluated with the Positive and Negative Syndrome Scale for their psychopathology. Based on a series of multiple linear regression analyses, we derived a model accounting for the relationships among the specific domains of psychopathology and red herring (RH) items of the Liverpool University Neuroleptic Side Effects Rating Scale in predicting subjective side effects. The model with anxiety/depressive symptoms and RH serving as mediators between positive symptoms and side effects was found to show good fit. Positive symptoms caused mostly anxiety symptoms and tendency to report RH items, whereby resulting in over-generalized reporting of subjective side effects. However, a large proportion of variance of side effects was explained by RH, which was only partially explained by positive symptoms alone. Therefore, patients with severe levels of positive and anxiety/depressive symptoms may be prone to nocebo-like effects of antipsychotics. Studies that include acute stage patients presenting severe levels of these symptoms should not rely only on the subjective report of side effects but also apply objective measures. Int Clin Psychopharmacol 25: 83-90 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.ko_KR
dc.description.sponsorshipThis study was supported by a grant (03-PJ10-PG13-
GD01-0002) of the Korea Health 21 R&D project,
Ministry for Health, Welfare and Family Affairs, Republic
of Korea.
ko_KR
dc.language.isoenko_KR
dc.publisherLIPPINCOTT WILLIAMS & WILKINSko_KR
dc.subjectnocebo effectko_KR
dc.subjectpsychopathologyko_KR
dc.subjectred herringko_KR
dc.subjectschizophreniako_KR
dc.subjectLiverpool University Neuroleptic Side Effects Rating Scaleko_KR
dc.subjectsubjective side effectsko_KR
dc.titleThe effects of psychopathology on subjective experience of side effects of antipsychotics in patients with schizophreniako_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor정동청-
dc.contributor.AlternativeAuthor안용민-
dc.contributor.AlternativeAuthor김세현-
dc.contributor.AlternativeAuthor김용식-
dc.identifier.doi10.1097/YIC.0b013e328334e5a8-
dc.citation.journaltitleINTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY-
dc.description.citedreferenceYilmaz Y, 2009, EUR J PAEDIATR NEURO, V13, P439, DOI 10.1016/j.ejpn.2008.08.007-
dc.description.citedreferenceAhn YM, 2009, J CLIN PSYCHOPHARM, V29, P117, DOI 10.1097/JCP.0b013e31819a6995-
dc.description.citedreferenceLincoln TM, 2007, SCHIZOPHRENIA BULL, V33, P1324, DOI 10.1093/schbul/sbm002-
dc.description.citedreferenceReeves RR, 2007, GEN HOSP PSYCHIAT, V29, P275, DOI 10.1016/j.genhosppsych.2007.01.010-
dc.description.citedreferenceBenedetti F, 2006, J NEUROSCI, V26, P12014, DOI 10.1523/JNEUROSCI.2947-06.2006-
dc.description.citedreferenceDay JC, 2005, ARCH GEN PSYCHIAT, V62, P717-
dc.description.citedreferenceBENTLER PM, 1990, PSYCHOL BULL, V107, P238-
dc.description.citedreferenceMCLOUGHLIN C, 1992, ANAESTHESIA, V47, P202-
dc.description.citedreferenceHOGAN TP, 1992, PSYCHOL MED, V22, P347-
dc.description.citedreferenceLINDENMAYER JP, 1994, PSYCHIAT QUART, V65, P299-
dc.description.citedreferenceDAY JC, 1995, BRIT J PSYCHIAT, V166, P650-
dc.description.citedreferenceDAVIS C, 1995, J CLIN PSYCHOPHARM, V15, P347-
dc.description.citedreferenceCoukell AJ, 1996, CNS DRUGS, V6, P237-
dc.description.citedreferenceAwad AG, 2000, SCHIZOPHRENIA BULL, V26, P557-
dc.description.citedreferenceCabeza IG, 2000, SCHIZOPHR RES, V41, P349-
dc.description.citedreferenceSIMPSON GM, 1970, ACTA PSYCHIAT SCAN S, V212, P11-
dc.description.citedreferenceHOGAN TP, 1983, PSYCHOL MED, V13, P177-
dc.description.citedreferenceLINGJAERDE O, 1987, ACTA PSYCHIATR SCA S, V334, P1-
dc.description.citedreferenceKAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261-
dc.description.citedreferenceBARNES TRE, 1989, BRIT J PSYCHIAT, V154, P672-
dc.description.citedreferenceYI JS, 2001, J KOREAN NEUROPSYCHI, V40, P1090-
dc.description.citedreferenceNaber D, 2001, SCHIZOPHR RES, V50, P79-
dc.description.citedreferenceAHN YM, 2002, J KOREAN NUEROPSYCHI, V41, P876-
dc.description.citedreferenceAHN YM, 2002, J KOREAN NEUROPSYCHI, V41, P890-
dc.description.citedreferenceJUNG HY, 2002, J KOREAN NEUROPSYCHI, V41, P138-
dc.description.citedreferenceBarsky AJ, 2002, JAMA-J AM MED ASSOC, V287, P622-
dc.description.citedreferencede Haan L, 2002, PSYCHOPHARMACOLOGY, V162, P24, DOI 10.1007/s00213-002-1054-x-
dc.description.citedreferenceKim JH, 2002, COMPR PSYCHIAT, V43, P456, DOI 10.1053/comp.2002.35908-
dc.description.citedreferenceFountoulakis KN, 2003, BRIT J PSYCHIAT, V182, P81-
dc.description.citedreferenceLambert TJR, 2003, HUM PSYCHOPHARM CLIN, V18, P405, DOI 10.1002/hup.495-
dc.description.citedreferenceLee KH, 2003, PSYCHOPATHOLOGY, V36, P226, DOI 10.1159/000073447-
dc.description.citedreferenceLehman AF, 2004, AM J PSYCHIAT, V161, P1-
dc.description.citedreferenceCarrick R, 2004, PSYCHOL PSYCHOTHER-T, V77, P19-
dc.description.citedreferenceRitsner M, 2004, J CLIN PSYCHOPHARM, V24, P245, DOI 10.1097/01.jp.0000125684.82219.53-
dc.description.citedreferenceJung HY, 2005, HUM PSYCHOPHARM CLIN, V20, P41, DOI 10.1002/hup.655-
dc.description.citedreferenceNABER D, 2005, ACTA PSYCHIAT SCAND, V427, P29-
dc.description.citedreferenceUllman JB, 2006, J PERS ASSESS, V87, P35-
dc.description.citedreferenceWilliamson A, 2007, NEUROTOXICOLOGY, V28, P227, DOI 10.1016/j.neuro.2006.03.009-
dc.description.citedreferenceBell M, 2007, PSYCHIAT RES, V151, P37, DOI 10.1016/j.psychres.2006.04.012-
dc.description.citedreferenceHwang SSH, 2009, J NERV MENT DIS, V197, P79, DOI 10.1097/NMD.0b013e318196083c-
dc.description.citedreferenceBEBBINGTON PE, 2009, ACTA PSYCHIAT SCAN S, V438, P22-
dc.description.citedreferenceVoruganti LP, 2008, CURR OPIN PSYCHIATR, V21, P133-
dc.description.citedreferenceFoster JM, 2008, PHARMACOEPIDEM DR S, V17, P278, DOI 10.1002/pds.1533-
dc.description.tc0-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share